Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis

• Status: Unknown status
• Trial end date: 2019-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients with moderate to severe plaque psoriasis will be treated with Otezla BID. At week 8, non responders will be discontinued, partial responders will be given add-on Enstilar QD for 4 weeks and PASI 75 responders will remain on Otezla monotherapy through week 16.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Psoriasis Treatment Center of Central New Jersey
• Collaborator: Celgene Corporation
• Treatments: Apremilast; Calcipotriene

Criteria

Inclusion Criteria:

1. Male or female adult ≥ 18 years of age;

2. Diagnosis of chronic plaque-type psoriasis

3. Moderate to severe plaque type psoriasis as defined at baseline by:

• PGA score of 3 or greater

• BSA affected by plaque-type psoriasis of 10% or greater

• PASI ≥ 12

4. Able and willing to give written informed consent prior to performance of any study-related procedures

5. Must be in general good health (except for disease under study) as judged by the Investigator, based on medical history, physical examination, clinical laboratories, and urinalysis. (NOTE: The definition of good health means a subject does not have uncontrolled significant co-morbid conditions).

Exclusion Criteria:

1. Other than psoriasis, any clinically significant (as determined by the investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is uncontrolled.

2. Forms of psoriasis other than chronic plaque-type (e.g., Pustular erythrodermic and/or guttate psoriasis) or drug induced psoriasis

3. Subjects who previously used any biologic agent for psoriasis.

4. Use of oral systemic medications for the treatment of psoriasis within 4 weeks (includes, but not limited to, oral corticosteroids, methotrexate, acitretin and cyclosporine).

5. Patient used topical therapies to treat psoriasis on the hands and/or feet within 2 weeks of the Baseline Visit (includes, but not limited to, topical corticosteroids, vitamin D analogs, or retinoids).

6. Patient received UVB phototherapy within 2 weeks of Baseline.